Oramed Pharmaceuticals Inc at Canaccord Genuity Growth Conference Transcript
Good afternoon, everyone. Thank you for joining us again. My name is Edward Nash, Senior Biotechnology Analyst here at Canaccord Genuity. It's my pleasure to have with us today, Michael Rabinowitz, who is the Chief Commercial Officer of Oramed Pharmaceuticals, a name that we currently cover with a buy rating.
So welcome, Michael. Just wanted to maybe jump right into things by having you give us a little bit of background on the company, and its current ongoing R&D pipeline just from a 10,000 foot view.
Sure. And first, let me thank Ed and everyone involved with the conference. It's such a pleasure to be here, be able to meet with so many investors in person for a change, some great meetings already. So, thank you very much.
For those of you who don't know me, I'm the Chief Commercial Officer, as Ed said, at Oramed, with responsibilities across business development, licensing, all the commercial strategy clearly,
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
